ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,447.90
0.14%
S&P ASX All Technology
3,966.40
0.06%
Brent Oil
72.825
1.04%
US Dollar vs AUD
1.54571
0.49%
Bitcoin
95,746.15
-1.56%
Pepperstone
Advertisement
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Sigilon Therapeutics Inc (SGTX)

  7. Sigilon Therapeutics Inc (SGTX) News

SGTX

Sigilon Therapeutics (SGTX)

Sigilon Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SGTX
DateTimeSourceHeadlineSymbolCompany
21/08/202322:22Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:SGTXSigilon Therapeutics Inc
16/08/202314:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SGTXSigilon Therapeutics Inc
14/08/202321:25PR Newswire (US)Lilly Completes Acquisition of Sigilon TherapeuticsNASDAQ:SGTXSigilon Therapeutics Inc
12/08/202306:28Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGTXSigilon Therapeutics Inc
12/08/202306:26Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGTXSigilon Therapeutics Inc
12/08/202306:24Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGTXSigilon Therapeutics Inc
12/08/202306:22Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGTXSigilon Therapeutics Inc
12/08/202306:20Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:SGTXSigilon Therapeutics Inc
12/08/202306:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGTXSigilon Therapeutics Inc
12/08/202306:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
12/08/202306:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
12/08/202306:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
10/08/202322:31Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:SGTXSigilon Therapeutics Inc
07/08/202322:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SGTXSigilon Therapeutics Inc
02/08/202306:06Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:SGTXSigilon Therapeutics Inc
28/07/202306:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
25/07/202309:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
19/07/202306:03Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:SGTXSigilon Therapeutics Inc
13/07/202322:18Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:SGTXSigilon Therapeutics Inc
29/06/202321:35Dow Jones NewsEli Lilly to Acquire Sigilon TherapeuticsNASDAQ:SGTXSigilon Therapeutics Inc
29/06/202321:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SGTXSigilon Therapeutics Inc
29/06/202321:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGTXSigilon Therapeutics Inc
29/06/202320:57Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:SGTXSigilon Therapeutics Inc
29/06/202320:45PR Newswire (US)Lilly to Acquire Sigilon TherapeuticsNASDAQ:SGTXSigilon Therapeutics Inc
23/05/202306:38Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SGTXSigilon Therapeutics Inc
23/05/202306:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
23/05/202306:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
23/05/202306:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
23/05/202306:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
23/05/202306:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SGTX

Your Recent History

BIT
C50
Exchange Traded
BOV
TJXC34Q
TJX Companies
TSXV
CBAR.P
Castlebar Capital
TSXV
BHR
Blackheath Resources
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for ASX Level 1 & 2

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $1958.40 only $783.36